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Introduction 
1. INTRODUCTION 
 
The clinical picture of dementia as a deterioration in cognition in 
later years has been recognized for centuries but understood in its current 
formulation only for the past three decades. In the late 19th and early 20th 
centuries the shift in the conceptualization of mental illness away from 
moral causation towards disease etiologies extended to dementia, which 
was then conceived as an effect of aging and related to arteriosclerosis. 
Alzheimer’s disease (AD) did not emerge as a distinct disease until the 
mid-20th century, which led to the recognition of multiple diseases of 
cognition with different etiologies. The dementias can be categorized 
according to clinical presentation, neuropathology and/or etiology. 
Parkinson’s group (including Lewy Body disease, dementia of Parkinson’s 
and Alzheimer’s dementia with Parkinson’s); the frontotemporal group 
(including Pick’s disease and Semantic dementia); and the vascular group 
(including large and small vessel disease).  
 
1.1 ALZHEIMER’S DISEASE 
 
AD is the most common form of dementia, accounting for 50–60% 
of all cases. The prevalence of dementia is below 1% in individuals aged 
60–64 years, but shows an almost exponential increase with age, so that in 
people aged 85 years or older the prevalence is between 24% and 33% in 
the Western world. Representative data from developing countries are 
sparse, but about 60% of patients with dementia are estimated to live in this 
part of the world. AD is very common and thus is a major publichealth 
problem. In 2001, more than 24 million people had dementia, a number that 
is expected to double every 20 years up to 81 million in 2040 because of 
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the anticipated increase in life expectancy. Besides ageing, which is the 
most obvious risk factor for the disease, epidemiological studies have 
suggested several tentative associations. Some can be linked to a decreased 
reserve capacity of the brain, including reduced brain size, low educational 
and occupational attainment, low mental ability in early life, and reduced 
mental and physical activity during late life. The brain reserve capacity is 
determined by the number of neurons and their synaptic and dendritic 
arborisation together with lifestyle-related cognitive strategies. A low 
reserve capacity has been linked with early presentation of some 
pathological changes of the disease. Moreover, several epidemiological 
studies have shown that head injury could be a risk factor (Blennow k, 
2006). 
 
1.1.1 CLINICAL FEATURES 
Short-term memory loss and visual-spatial confusion are one of the earliest 
clinical manifestations in AD. As the disease progresses, symptoms include 
confusion, irritability and aggression, mood swings, language breakdown, 
long-term memory loss, and the general withdrawal of the sufferer as their 
senses decline and patients are unable to recognize familiar objects or 
persons. Gradually, bodily functions are lost, ultimately leading to death. 
Individual prognosis is difficult to assess, as the duration of the disease 
varies. AD develops for an indeterminate period of time before becoming 
fully apparent, and it can progress undiagnosed for years. The mean life 
expectancy following diagnosis is approximately seven years. Fewer than 
three percent of individuals live more than fourteen years after diagnosis 
(Oddo, 2008). Because AD cannot be cured and is degenerative, 
management of patients is essential. The role of the main caregiver is often 
taken by the spouse or a close relative. Alzheimer's disease is known for 
placing a great burden on caregivers; the pressures can be wide-ranging, 
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involving social, psychological, physical, and economic elements of the 
caregiver's life. In developed countries, AD is one of the most 
economically costly diseases to society. 
 
1.1.2 ETIOLOGY AND PATHOGENESIS OF AD 
AD is named after Dr. Alois Alzheimer, German doctor who in 1907 
noticed changes in the brain tissue of a woman who had died of an unusual 
mental illness. There is a loss of nerve cells in areas of the brain that are 
vital to memory and other mental abilities. In AD, the progressive nature of 
neurodegeneration suggests an age-dependent process that ultimately leads 
to degeneration of synaptic afferent systems, dendritic and neuronal 
damage, and the formation of abnormal protein aggregates throughout the 
brain. The age-related susceptibility of the brain to neurodegenerative 
disease may be inherent in the susceptibility of individual neurons to 
various stressors. AD is accompanied by three main structural changes in 
the brain: diffuse loss of neurons, intracellular protein deposits termed 
neurofibrillary tangles (NFT) consisting of hyperphosphorylated tau protein 
and extracellular protein deposits termed amyloid (βA) or senile plaques, 
surrounded by dystrophic neurites. Genome scale analysis revealed marked 
differences in gene expression between AD and normal brain. Such 
analysis is a potentially powerful approach to listing genes related to the 
pathogenesis. 
 
1.1.3 MOLECULAR MECHANISMS 
Two major hypothesis have been postulated to explain the molecular 
mechanism of disease: the cholinergic hypothesis and the amyloid cascade 
hypothesis. Many studies support the cholinergic hypothesis, showing that 
a dysfunctional cholinergic system is sufficient to produce memory deficit 
in animal models that are analogous to Alzheimer’s dementia. Brains from 
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AD patients show degeneration of cholinergic neurons of the basal fore 
brain. A marked decline in cholinergic markers, choline acetyltransferase 
and acetyl cholinesterase has been reported in the cerebral cortex of AD 
brain. Although cholinergic deficits cannot fully account for the overall 
neuropathological features observed in AD, it represents a significant part 
of AD etiology and further research regarding the preferential vulnerability 
of this system in AD is warranted. The other hypothesis, the amyloid 
cascade hypothesis states that the neurodegenerative process observed in 
AD brains is a series of events triggered by the abnormal processing of the 
APP that causes production, aggregation, deposition and toxicity of its βA 
derivative. Currently the amyloid cascade hypothesis has received 
considerable support from molecular genetic studies. Several genes have 
been localized and/or identified in AD patients. It may be possible, for 
example, to correlate specific biochemical reactions with changes in these 
functions. At least four genes are implicated in the pathophysiology of AD 
such as mutations of the APP gene14 on chromosome 21, polymorphism of 
the apolipoprotein E (ApoE) on chromosome 19 and mutations in the 
presenilin 1 (PS1) and presenilin 2 (PS2) genes on chromosome 14 and 1, 
respectively. Mutation in either the APP gene on chromosome 21 or 
presenilin (PS) gene that increase the βA production have been described in 
a modest number of patients with familial early onset AD. This peptide is 
derived from the membrane bound APP which can be processed via two 
distinct processing pathways: the amyloidogenic pathway that liberates the 
βA peptide and the nonamyloidogenic pathway which precludes the 
formation of βA and instead generates a secreted form of APP, sAPPa. The 
proponents of the amyloid cascade hypothesis argue the increased 
production of the longer amyloid peptide βA1–42, which forms the plaque 
core. This βA1–42 peptide goes on to induce all the subsequent pathology 
including tau aggregation, phosphorylation, neuronal attrition and chemical 
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dementia. However, all the molecular and cellular events occurring in 
different forms of AD cannot be explained by classical amyloid hypothesis. 
Mechanisms have emerged in which the fibrillar amyloid deposits does not 
act as the primary effector of this neurodegeneration. No correlation has 
been reported between senile plaques and the degree of dementia. Most of 
the experiments conducted on βA toxicity have been performed with a 
suspension of fibrils. Recent studies have detected novel and stable 
intraneuronal pools of insoluble βA deposits, which are generated in the 
endoplasmic reticulum/intermediate compartment (ER/IC), challenging the 
prevailing view that βA deposition is initiated in the extracellular space by 
the secretion of βA peptide. Accordingly, it has been observed that 
intracellular deposits of βA are mainly concentrated in detergent insoluble 
glycolipid enriched membrane domains. It is presently thought that the 
amyloidogenic process that converts soluble βA from its relatively inert 
form to its putative pathogenic state into amyloid fibrils, is a nucleation-
dependent process that probably requires structural transitions of βA. An 
amyloid deposit might be seeded with βA derived locally from 
disintegrating neuronal membrane or from the insoluble pool rather than 
from diffuse βA deposits or from secreted βA This internalization could 
lead to a protection of the cells against βA peptide by its total clearance or 
to cell death through long term intracellular aggregation. 
 
Amyloidogenesis: 
Amyloid plaques in AD are not constituted by a single protein derived from 
APP. Many proteins, such as proteases, protease inhibitors, and 
microtubule-associated proteins (e.g., tau), are deposited in plaques. ApoE 
also associates with AD plaques. These additional plaque-associated 
proteins may contribute to the aggregation of the β-peptide into fibrils and 
the formation of insoluble βA arrays within the extracellular space. 
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Regardless of the underlying amyloid fibril protein/peptide or associated 
disease, isolated amyloid fibrils when examined by negative staining or 
high resolution electron microscopy are composed of multiple filaments or 
protofibrils twisted around each other forming nonbranching fibrils 
typically 7–10 nm in diameter with a crossed β-pleated sheet conformation. 
βA has the propensity of self-aggregation and facilitate nucleation-
dependent polymerization of the shorter form. Studies have shown that 
aggregation might be modulated by some of the proteins present in senile 
plaques. Factors responsible for or inducing aggregation of peptide, as well 
as the cellular context in which it occurs, have yet to be established. All 
evidence in favor of fibrillation, over production of βA, decreased 
clearance of secreted βA and involvement of aggregating factors, might 
lead to neurodegeneration. 
 
Role of APP and secretases: 
Amyloid precursor protein is a 770 residue ubiquitous glycosylated 
transmembrane protein with a large hydrophilic aminoterminal 
extracellular domain, a single hydrophobic putative transmembrane domain 
and a small carboxy-terminal cytoplasmic domain. It is the source of βA 
peptide found in neuritic plaques of AD. A single transmembrane domain 
consisting of 23 residues. APP is coded by a single copy gene located on 
the mid portion of the long arm of human chromosome 21. The APP 
proteins mature in the endoplasmic reticulum and Golgi apparatus and 
exhibit post-translational modifications, including phosphorylation, 
glycosylation and sulfation. However, the abnormal processing of the APP 
triggers the aggregation, deposition and toxicity of its βA derivative. The 
production of βA from APP is dependent upon the activities of two 
enzymes β-secretase and γ-secretase. On its way to the cell surface, two 
different proteases, α- and β-secretase can cleave at different positions 
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within the APP molecule leading to the release of the large soluble N-
terminal fragments, α-APPs and β-APPs, respectively (Fig. 1). Cleavage by 
α-secretase occurs within the region containing βA and thus precludes 
formation of βA. In contrast, β-secretase cleavage generates the free N-
terminus of βA and is therefore considered the first critical step in amyloid 
formation. Two C-terminal fragments C83 and C99 are also produced by α-
secretase and β-secretase, respectively. Both C83 and C99 can be further 
cleaved by γ-secretase, within the APP transmembrane domain which leads 
to the release and secretion of βA from C99 and of p3, a shortened, 
presumably nonpathogenic, βA from C83. Mutations in genes of APP and 
presenilins have been shown to modify the processing of APP, through 
modulation of secretase activities. This altered processing leads to an 
increase in βA. It might trigger aggregation and induce the 
neurodegeneration process. 
 
 
Figure 1. The amyloid-β precursor protein (APP) is processed by α-secretase (non-
amyloidogenic pathway) or β-secretase (amyloidogenic pathway) with βA generation.  
 
Role of tau proteins: 
Almost in parallel with the identification of βA in plaques, tangles were 
shown to be composed of abnormally hyperphosphorylated tau protein. Tau 
is a normal axonal protein that binds to microtubules through its 
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microtubule-binding domains, thereby promoting microtubule assembly 
and stability. Tau phosphorylation is regulated by the balance between 
multiple kinases and phosphates. Tau hyperphosphorylation in Alzheimer’s 
disease starts intracellularly and leads to sequestration of normal tau and 
other microtubule-associated proteins, which causes disassembly of 
microtubules and thus impaired axonal transport, compromising neuronal 
and synaptic function. Tau also becomes prone to aggregation into 
insoluble fibrils in tangles, further compromising neuronal function. Tau 
pathology starts early in the disease process in neurons in the 
transentorhinal region, spreads to the hippocampus and amygdala, and later 
to the neocortical association areas. Whether tau hyperphosphorylation and 
tangle formation are a cause or consequence of Alzheimer’s disease is 
unknown (Blennow, 2006). 
 
1.2 PATHOLOGICAL ROLE OF AMYLOID IN AD 
 
Diverse lines of evidence suggest that βA plays a central role in the 
pathogenesis of neuronal dysfunction in AD, yet the βA hypothesis remains 
controversial, not least because the quantity and temporal progression of 
amyloid plaques do not show a simple relationship to the clinical 
progression of the disease. 
 
1.2.1 THE EMERGING ROLE OF SOLUBLE βA 
Recent studies suggest that the relatively weak correlation between plaque 
burden and severity of cognitive impairment may be explained by the 
activity of multiple different βA assembly forms and that early memory 
impairment may be mediated by soluble low-n oligomers. At ambient or 
body temperature and at concentrations 10–20 µM, both synthetic βA1-40 
and βA1-42 self-associate to form low-n oligomers, PFs (protofibrils) and 
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fibrils (Fig. 2). An important caveat when considering the cellular effects of 
different βA assemblies is the highly dynamic nature of βA aggregation. 
Because intermediates can further associate into higher-ordered aggregates, 
it is difficult to unambiguously ascribe cytopathological activity to a 
discrete species. However, amyloid oligomers, which represent 
intermediates in the fibril formation process may be primarily responsible 
for amyloid pathogenesis, rather than the mature fibrils that accumulate as 
large aggregates (Irvine, 2008). 
 
 
 
Figure 2: Production of βA by proteolytic cleavage from APP followed by association 
of βA to form oligomers and fibrils. 
 
1.2.2 COMMON PATHWAY OF AMYLOID FORMATION 
Amyloid fibrils accumulate in degenerative diseases as a consequence of 
the intermolecular hydrogen bonding of extended polypeptide strands that 
arise as a consequence of protein mis-folding. Amyloids from different 
diseases may share a common pathway for fibril formation. The initiating 
event is protein mis-folding or denaturation, which results in the acquisition 
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of the ability to aggregate in an infinitely propagating fashion. Quasi-stable 
intermediate aggregates ranging from dimers up to particles of a million 
Dalton or greater have been observed by a variety of methods. Soluble 
spherical aggregates of approximately 3-10 nm have been observed for 
many different types of amyloids by electron and atomic force microscopy 
and these spherical oligomers appear to represent intermediates in the 
pathway of fibril formation. These spherical particles have also been called 
micelles, prefibrillar aggregates, protofibrils and ADDLs. At longer 
aggregation times, curvilinear fibers form that have a beaded appearance 
form. These structures have also been called “protofibrils” because they 
appear to be formed by the coalescence of the spherical subunits. Finally, 
these structures either anneal or undergo a conformational change to form 
mature 6-10 nm cross-fibrils that have either a smooth or helical 
morphology (Glabe, 2006; Harper, 1997). Amyloids also have a number of 
structural features in common. Amyloid fibrils have a “cross-β” structure, 
which indicates that the backbone hydrogen bonding is parallel to the fibril 
axis. Amyloids also bind characteristic dyes, like Congo red and thioflavin 
dyes, which may be a reflection of their common cross-β structure (LeVine, 
1993). Amyloid oligomers also display a common structural motif that is 
distinct from fibrils based on the observation that a conformation 
dependent antibody specifically recognizes a common epitope on amyloid 
oligomers, but not fibrils, monomers or natively folded proteins for many 
different types of proteins. This indicates that the antibody recognizes a 
generic polypeptide backbone epitope that is independent of the amino acid 
sequence, but yet is shared in common among all types of amyloid 
oligomers. The anti-oligomer antibody also generically inhibits the toxicity 
of soluble oligomers examined in vitro (Kayed, 2003). 
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Pathogenic pathways of amyloid oligomers 
The permeabilization of membranes by amyloid oligomers that is a 
common component of amyloid toxicity may represent the primary 
common mechanism of amyloid pathogenesis. It may initiate a series of 
downstream pathological events that represents a common pathway of 
degeneration in amyloid-related diseases. These events that may lie 
immediately downstream from membrane permeabilization may constitute 
a core group of common pathological events that ultimately result in cell 
dysfunction and death. Membrane permeabilization by amyloid oligomers 
and the concomitant increase in intracellular calcium may be the proximate 
initiator of several pathogenic pathways, including reactive oxygen species 
(ROS) production, altered signaling pathways and mitochondrial 
dysfunction. Many signaling pathways are regulated directly or indirectly 
by intracellular Ca2+ levels or membrane depolarization, including 
pathways leading to up regulation of autophagy and cell death. In 
particular, accumulation of Ca2+ in the matrix of mitochondria leads to an 
increase in ROS production, cytochrome C release and apoptosis. Amyloid 
oligomers may also directly permeabilize the mitochondrial membrane 
(Hashimoto, 2003). Thus, the increase in energy demand necessary to 
maintain ion homeostasis and membrane polarization may also be a source 
of mitochondrial stress. Mitochondrial dysfunction may also feed back to 
upstream pathways that regulate the level of mis-folded proteins because 
many chaperones and the proteasome system utilize ATP. Chronic 
inflammation may also be a component of the core degenerative pathway 
as it is frequently observed in neurodegenerative diseases. The failure to 
efficiently clear amyloid aggregates may also contribute to pathogenesis by 
stimulating autophagic programmed cell death. 
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1.2.3 THE INVOLVEMENT OF THE UBIQUITIN-PROTEASOME 
SYSTEM IN AD 
The accumulation of βA and tau makes AD a proteins-misfolding disease 
and suggests that alterations in protein quality control mechanisms may be 
directly or indirectly involved in the disease pathogenesis. Protein 
clearance by the UPS occurs in two sequential steps, a tagging reaction and 
a subsequent degradation of the tagged proteins by the proteasome system 
(Oddo, 2008). Ubiquitin is a small, highly conserved peptide present in all 
eukaryotic cells that is conjugated to the proteins that needs to be targeted 
to the proteasome. This process occurs in three steps. First an ubiquitin 
monomer is activated in an ATP-dependent reaction by the ubiquitin-
activating enzyme (E1). Subsequently ubiquitin is transferred to an 
ubiquitin conjugating enzyme (E2). In the final step, ubiquitin is transferred 
to the target protein viaan ubiquitin ligase (E3). The E3 ligase binds both 
the target protein and the complex E2-ubiquitin and facilitates the 
formation of a covalent bond between the ubiquitin monomer from the E2 
enzyme and the target protein. Activated ubiquitin molecules are 
sequentially added to the first ubiquitin proteins to form a polyubiquitin 
chain. Proteins tagged with chains of four or more ubiquitins are 
recognized by the 26S proteasome for degradation. It is the E3 ligase that 
confers specificity to the process by selectively binding to a protein target. 
Ubiquitin monomers are liberated after proteasome degradation or are 
actively removed by the ubiquitin carboxyl-terminal hydrolases (Fig. 3) 
(Layfield, 2003). 
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UPS 
Figure 3: Overview of the ubiquitin–proteasome system (UPS). The protein 
ubiquitination pathway. Ubiquitin (Ub) is activated by E1 and transferred to the E2 
enzyme and is, finally, conjugated to substrate proteins with a specific E3 ligase. 
Further polyubiquitination is required to target proteins for degradation. 
 
Growing evidence suggest that alterations in the UPS function may be 
involved in AD pathogenesis. This view is supported by evidence showing 
that in AD brains ubiquitin accumulates in both plaques and tangles. It has 
also been shown that these structures contain ubiquitin-B mutant protein 
(UBB+1), a mutant ubiquitin carrying a 19-amino acid C-terminal 
extension generated by a transcriptional dinucleotide deletion. Notably, 
UBB+1 has been shown to block ubiquitin-dependent proteolysis in 
neuronal cells, to cause neuritic beading of mitochondria in associating 
with neuronal differentiation and it has been suggested to be a mediator of 
βA-induced neurotoxicity. The AD brain is also characterized by the 
accumulation of oxidized proteins, which may further exacerbate the 
decrease in proteasome activity. These data strongly argue that 
dysfunctional UPS function may be involved in AD pathogenesis (Oddo, 
2008). 
 
1.2.4 ROLE OF GLIAL CELLS IN AD 
Glial cells are not only essential for maintaining a healthy well-functioning 
brain, but they also protect and aid the brain in the functional recovery 
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from injuries. The activation of glial cells in the CNS is the first defence 
mechanism against pathological abnormalities that occur in 
neurodegenerative diseases. Different signals can mediate and influence the 
fate of glial cell activation. A dysfunction of glial cell receptors, which 
alters the glial cells sense of their environment, can lead to the development 
of neurological diseases. Emerging evidences suggest that changes in the 
dividing process of glial cells during aging might lead to their abnormality 
and may provide clues to the pathogenesis of devastating diseases, such as 
AD. Nevertheless, because there is such diversity among each glia family 
(astrocyte, microglia and oligodendrocyte), they are still a mystery that 
holds the key to their modification. However, glial cell plasticity and 
diversity may allow the maturation of new functional cells, which can help 
the neuronal repair process (Farfara, 2008). In particular, besides a role 
mainly fagocitic, microglia activation plays multiple roles in modulating 
the stress response of neuronal cells and eventually the neuronal death and 
survival. Microglia can secrete various trophic factors, such as 
transforming growth factor beta and neurotrophins that could potentially 
increase the survival of damage neurons. It has been suggest that a proper 
regulation of microglial response to injury will arrest neuronal damage and 
promote neuronal survival, whereas a failure in the regulation will lead to 
chronic neurodegeneration. This suggest that the ability of microglia to 
induce or prevent neuronal death depends on reciprocal cellular interactions 
as well as on signals arising from injured neurons (Streit, 1999). 
 
1.2.5 APOPTOSIS IN AD 
The final step in AD is characterized by βA-induced apoptosis, a 
mechanism of cellular death activated by mitochondrial pathway or by the 
interaction with specific neuronal cell-surface receptors. 
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Mammalian apoptosis is regulated by the Bcl-2 family of proteins, the 
adaptor protein Apaf-1 (apoptotis protease-activating factor 1) and the 
cysteine protease caspase family. Neurons share the same basic apoptosis 
programme with all other cell types. However, different types of neurons, 
and neurons at different developmental stages, express different 
combinations of Bcl-2 and caspase family members, which is one way of 
providing the specificity of regulation. The Bcl-2 family of proteins has a 
crucial role in intracellular apoptotic signal transduction. This gene family 
includes both anti-apoptotic and pro-apoptotic proteins that contain one or 
more Bcl-2 homology domains. The major anti-apoptotic members of the 
Bcl-2 family, Bcl-2 and Bcl-xL, are localized to the mitochondrial outer 
membrane and to the endoplasmic reticulum and perinuclear membrane. 
Bax is a pro-apoptotic member of the Bcl-2 family that is widely expressed 
in the nervous system. During apoptosis, cytosolic Bax is translocated to 
the mitochondrial membrane where it induces cytochrome c release. Once 
in the cytosol, cytochrome c is a co-activator of Apaf-1 in the cleavage of 
procaspase-9 and execution of apoptosis through the mitochondrial 
pathway. Exposure of cells to βA peptide has been shown to result in 
mitochondrial perturbation and subsequent caspase activation. In addition, 
βA induces cytochrome c release via direct mitochondrial membrane 
permeabilization, which appears to be associated with profound changes in 
membrane lipid and protein structure. Thus, βA peptide also modulate 
protein levels of Bcl-2 family members, resulting in up-regulation of pro-
apoptotic Bax and increased expression of anti-apoptotic Bcl-2. 
A central role for βA protein is also supported by the effects of genetic 
mutations that cause familial Alzheimer’s disease, all of which predispose 
to amyloid deposition, and by the observation that βA can be neurotoxic in 
vitro and in vivo. The toxicity of abnormal structural forms of βA provides 
a unifying theme with other age-related neurodegenerative disorders 
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characterized by the appearance of pathological protein structures. The 
mechanism of βA neurotoxicity and its precise cellular locus of action are 
unsettled, but it has been shown that βA can induce oxidative stress and 
elevate intracellular Ca2+ concentration. βA might induce apoptosis by 
interacting with neuronal receptors, including the receptor for advanced 
glycation endproducts (RAGE), which can mediate free-radical production, 
the p75 neurotrophin receptor, which can induce neuronal cell death, and 
the amyloid precursor protein, which can also induce neuronal cell death. 
These various βA-receptor interactions might activate several different cell-
death-signalling pathways (Fig. 4). For example, βA can activate a set of 
immediate early genes similar to those induced by trophic factor 
withdrawal, and can activate caspases. Furthermore, neurons deficient in 
caspase-2 and caspase-12 have decreased vulnerability to βA toxicity, 
suggesting that selective caspase inhibition might be a potential therapeutic 
approach in Alzheimer’s disease. Several recent studies suggest that 
presenilins might be λ-secretases, proteases that participate in the 
generation of βA, although this remains to be established definitively. 
Presenilin mutations can also increase neuronal vulnerability to apoptosis. 
Activation of microglial cells is a prominent feature of the inflammatory 
response in the brain in Alzheimer’s disease that is likely to contribute to 
neuronal cell death. Microglial activation is associated with amyloid 
plaques and can be induced experimentally by βA. βA-induced microglial 
activation results in the secretion of TNF-α and other toxic factors that can 
induce neuronal apoptosis. Similar microglial-based mechanisms have been 
implicated in other neurodegerative disorders. Thus, pathological neuronal 
cell death might be a direct consequence of toxic insults such as βA, or an 
indirect consequence of a complex interaction between neurons, microglia 
and toxic factors. 
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Figure 4: Cellular pathways of βA protein neurotoxicity in AD. 
 
1.3 THERAPEUTIC INTERVENTIONS 
 
With the advent of the new research on molecular mechanisms of 
AD pathogenesis, the promising prospects of development of drugs for the 
treatment of AD seem closer than ever. There probably is not one single 
cause, but several factors are important to describe the etiology of disease. 
Therefore, combination of compounds which act at more than one target 
site could be useful for the treatment (Parihar, 2004). Knowledge of the 
neurotransmitter disturbances in Alzheimer’s disease has led to the 
development of drugs with symptomatic e. ects, which are approved in 
many countries. Research advances in the molecular pathogenesis of 
Alzheimer’s disease have also led to new drug candidates with disease-
modifying potential, which have now come to testing in clinical trials. 
-   17 -
Introduction 
Epidemiological data have suggested additional drug candidates, some of 
which have been investigated in randomised trials. 
 
1.3.1 SYMPTOMATIC TREATMENTS 
Acetylcholinesterase inhibitors: The cholinergic hypothesis in Alzheimer’s 
disease states that degeneration of cholinergic neurons in the basal 
forebrain nuclei causes disturbances in presynaptic cholinergic terminals in 
the hippocampus and neocortex, which is important for memory 
disturbances and other cognitive symptoms. One therapeutic approach to 
enhance cholinergic neurotransmission is to increase the availability of 
acetylcholine by inhibiting acetylcholinesterase, the enzyme that degrades 
acetylcholine in the synaptic cleft. The acetylcholinesterase inhibitors 
donepezil, rivastigmine, and galantamine are approved for clinical use in 
Alzheimer’s disease. Benefits of acetylcholinesterase inhibitors are also 
seen for functional and behavioural symptoms. There is no evidence that 
these drugs differ in efficacy. They are not expected to change the natural 
course of Alzheimer’s disease, but only to temporarily mitigate some of the 
symptoms. 
 
Memantine: Glutamate is the major excitatory neurotransmitter in the 
brain. Under normal conditions, glutamate and the N-methyl-D-aspartate 
(NMDA) receptor have important roles for learning and memory processes. 
Under abnormal conditions, such as in Alzheimer’s disease, increased 
glutamatergic activity can lead to sustained low-level activation of NMDA 
receptors, which may impair neuronal function. Memantine is a non-
competitive NMDA-receptor antagonist that is believed to protect neurons 
from glutamate-mediated excitotoxicity without preventing the 
physiological NMDA-receptor activation needed for cognitive functioning. 
Memantine show modest positive effects on cognitive and behavioural 
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symptoms, and improved ability to perform activities. Additionally, 
combination therapy with donepezil and memantine show positive effects 
on symptoms relative to donepezil alone.  
 
Treatment of behavioural signs: Behavioural signs, such as aggression, 
psychomotor agitation, and psychosis (hallucinations and delusions), are 
very common in patients with Alzheimer’s disease, especially in the late 
stages of the disease. Such symptoms not only affect quality of life for 
patients and caregivers, but also contribute to care burden and economic 
cost. Atypical antipsychotic drugs produce fewer extrapyramidal side-
effects than do conventional neuroleptics, and are thus preferred for the 
management of psychosis or agitation. Risperidone and olanzapine reduced 
the rate of aggression, agitation, and psychosis. Alternative treatments 
include anticonvulsants, such as divalproate and carbamazepine, and short-
acting benzodiazepines, such as lorazepam and oxazepam. Additionally, 
the cholinergic deficits can contribute to the development of behavioural 
symptoms, and treatment with acetylcholinesterase inhibitors also shows 
improvements in behavioural symptoms. 
 
1.3.2 DRUG CANDIDATES WITH POTENTIAL DISEASE-
MODIFYING EFFECTS 
The major focus has been to inhibit brain βA production and aggregation, 
and to increase βA clearance from the brain. 
 
Secretase modulators:  
Because βA is so closely associated with AD, the proteases that generate 
this peptide β- and γ-secretase are the top targets for therapeutic 
development. The finding that BACE1 knockout mice have abolished βA 
production without any clinical phenotype made BACE1 inhibitors an 
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attractive therapeutic strategy. β-secretase inhibitors have been developed 
to reduce brain βA concentrations in Alzheimer’s disease transgenic mice. 
γ-Secretase is considerably more complicated than β-secretase. A single 
protein is responsible for β-secretase activity, whereas γ-secretase seems to 
be a complex of integral membrane proteins that includes presenilin. In 
particular, γ-secretase is composed of at least four integral membrane 
proteins (Fig. 5). The active site apparently resides in presenilin, an eight-
transmembrane protein that contains two crucial aspartate residues (Asp) 
that are required for γ-secretase activity. Presenilin is cleaved into two 
pieces (see arrow for cleavage site) that remain associated as heterodimers. 
Each piece contributes one of the key aspartate residues. Nicastrin, as well 
as the newly identified APH1 and PEN2 proteins, associate with presenilin 
heterodimers and are required for protease activity. CHO on Nicastrin 
symbolizes glycosylation: a highly glycosylated form of Nicastrin is 
associated with γ-secretase activity. 
 
 
Figure 5: Components of the γ-secretase complex. 
 
Despite the complexity of γ-secretase, identifying cellpermeable inhibitors 
has been easier for this proteas than for β-secretase. The probable reason is 
that the active site of γ-secretase is hydrophobic, which is reflected by the 
fact that the enzyme recognizes and cleaves transmembrane domains. So, 
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inhibitors of γ-secretase should also be hydrophobic to allow interaction 
with the enzyme, and this characteristic aids membrane permeability. Some 
of more potent inhibitors of γ-secretase are transition state mimics, 
benzodiazepine, sulphonamides, dipeptide and benzocaprolactam. For γ-
secretase there is a concern about adverse effects because it cleaves other 
substrates such as Notch, might be crucial to normal physiology. 
Nevertheless, γ -secretase inhibitors have been developed that do not affect 
Notch signalling, and have shown good tolerability in phase I studies. 
Drugs that stimulate α-secretase can shift APP processing towards the 
nonamyloidogenic pathway, thus reducing βA production. Bryostatin, a 
protein kinase C activator currently tested in clinical trials as an anticancer 
drug, substantially enhances α-secretase processing of APP and reduces 
brain βA1-42 concentrations in Alzheimer’s disease transgenic mice. 
 
βA immunotherapy: 
Another general strategy for preventing βA build-up is to enhance the 
clearance of this peptide. A novel approach is immunization, either actively 
with the βA peptide itself or passively with anti-βA antibodies. In 1999 has 
been reported the effects of immunizing with βA1-42 in transgenic mice 
harbouring an AD-causing mutant human APP, which normally develop 
βA-containing plaques within 3-6 months. Immunization at a young age 
(six weeks) prevented the formation of Aβ-containing plaques and 
subsequent AD-related neuropathological changes. Even the immunization 
of older mice (11 months old) led to a substantial reduction of plaque 
burden and pathology, raising the hope that this approach might not only be 
an effective means of prevention but could also possibly reverse some of 
the devastation in those already afflicted. Active immunization has been 
shown to reduce cognitive dysfunction in transgenic mice. 
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Similar results were obtained by use of passive immunisation with 
antibodies against βA. The effect might be mediated by anti-βA antibodies 
that bind to βA plaques and induce βA clearance by microglia, or 
alternatively bind soluble βA in the periphery, thereby driving an βA efflux 
from the brain. A related study by researchers showed that administration 
of anti-βA antibodies to transgenic mice leads to a rapid and large increase 
in peripheral βA levels and can reverse memory deficits. In this case, the 
antibodies apparently did not bind to brain βA deposits, indicating that the 
sequestration of plasma βA causes a marked reduction in βA deposition in 
the brain. Despite some discrepancies between the two studies, the overall 
results are promising, because they indicate that active immunization might 
not be necessary. Such findings are of immediate practical importance, as 
early clinical trials for active immunization with βA1-42 caused serious 
central nervous system (CNS) inflammation in a small, but unacceptable, 
fraction of the subjects. Passive immunization might not be the only 
solution to this problem; other strategies include conjugating βA or βA 
epitopes to carrier proteins. 
 
βA fibrillisation inhibitors: 
Small peptides that interfere with βA-βA or βA-ApoE interactions can 
prevent the conformational change of βA to β-sheet structure and 
subsequent fibrillisation. Two such peptides have been shown to reduce βA 
fibrillisation in vitro and brain βA load in Alzheimer’s disease transgenic 
mice, without inducing an immune response. Glycosaminoglycans bind βA 
and can promote its aggregation. The drug candidate NC-531 (Alzhemed) 
is a glycosaminoglycan mimetic designed to interfere with the association 
between glycosaminoglycans and βA, but the paucity of publications 
precludes a more detailed review. A phase III clinical trial is ongoing. 
Copper and zinc ions can induce βA aggregation and toxic effects. The 
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metal chelator clioquinol (PBT-1) reduces brain βA deposition in 
Alzheimer’s disease transgenic mice. A small phase II trial showed 
marginal cognitive improvements with clioquinol, but because of toxic 
impurities (a di-iodo form of clioquinol) during production, further clinical 
trials have been halted. A new drug, PBT-2, which does not contain iodine, 
is currently undergoing clinical trials. 
 
Anti-tau drugs: 
In addition to amyloid deposits, the AD brain is also characterized by 
intraneuronal tangles that contain a filamentous form of the microtubule-
associated protein tau. Hyperphosphorylation of tau leads to the formation 
of paired helical filaments of this protein. These neuronal tau filaments 
develop after the initial deposition of amyloid, indicating that amyloidosis 
is an initial pathogenic event, with tau being a downstream mediator of 
neuronal toxicity. Modulating tau phosphorylation is therefore also 
considered to be a reasonable therapeutic strategy; particularly targeting the 
responsible kinases, such as cyclin-dependent kinase 5 (CDK5) and 
glycogen-synthase kinase-3β (GSK-3β), for inhibition. However, since tau 
phosphorylation is regulated by the balance between multiple kinases and 
phosphates, inhibition of a single kinase might be insufficient to normalise 
tau phosphorylation and the development of agents that selectively block 
these kinases is still in the early stages. 
 
1.3.3 DRUG CANDIDATES BASED ON EPIDEMIOLOGY 
Epidemiological studies have served as the theoretical basis for several 
treatment approaches. 
 
Anti-infiammatory drugs: 
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Plaques in Alzheimer’s disease are accompanied by local infiammatory 
characteristics, but whether the infiammation contributes to neurotoxic 
effects or represents a secondary reaction to βA deposition is unclear. Most 
epidemiological studies suggest that the risk of the disease is reduced in 
patients treated with non-steroidal anti-infiammatory drugs (NSAIDs). 
Several, but not all, NSAIDs reduce brain βA burden in Alzheimer’s 
disease transgenic mice, which may be mediated by either inhibition of 
cyclo-oxygenase (COX), or by a direct effect on γ-secretase, thereby 
reducing βA generation independently of COX inhibition. Clinical trials on 
anti-infiammatory drugs, including prednisone, hydroxychloroquine, and 
the selective COX-2 inhibitors celecoxib and rofecoxib, showed no effects 
on cognition in Alzheimer’s disease. The first large-scale clinical trial on 
both non-selective and COX-2 selective NSAIDs in the disease was also 
disappointing. One explanation is that these drugs might be protective only 
if given during mid-life, but will not reverse the degenerative process in 
patients with established pathology. A primary prevention trial of NSAIDs 
has been started to test whether they can be protective in patients with 
MCI. 
 
Cholesterol-lowering drugs: 
The first link between cholesterol and Alzheimer’s disease was suggested 
in a study reporting that rabbits fed with very high-cholesterol diet develop 
intracellular βA accumulation. However, when feeding Alzheimer’s disease 
transgenic mice a high-cholesterol diet, both reduced and increased brain 
βA load has been reported. Retrospective case-control studies suggesting 
that treatment with cholesterol-lowering drugs (statins) reduce the 
incidence of the disease have received much attention. Subsequent studies 
on Alzheimer’s disease transgenic mice also suggested that cholesterol-
lowering drugs diminish brain βA load. However, more recent prospective 
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cohort studies have not shown any association between statin use and 
reduced risk of the disease. Furthermore, treatment trials in patients with 
the disease have not reported any change in plasma or CSF βA1-42 and a 12-
month placebo controlled double-blind study on atorvastatin showed only 
borderline cognitive improvement. 
 
Oestrogens: 
Epidemiological studies have reported an association between reduced risk 
of dementia and postmenopausal oestrogen supplementation. Animal 
studies also suggest that oestrogens could have several beneficial effects on 
neuronal function. However, large randomised controlled clinical trials of 
oestrogens have not shown a reduced risk of the disease. 
 
Antioxidants: 
Large observational studies suggest that dietary intake of antioxidants, such 
as vitamin E, could reduce the risk of the disease. One randomised 
controlled clinical trial of vitamin E supplementation in the disease showed 
only a marginal effect on time to institutionalisation and need of care. 
However, another well-designed randomised controlled trial showed no 
effect of vitamin E supplementation on the rate of progression to 
Alzheimer’s disease in MCI. 
 
The fact that AD involves progressive cognitive deterioration, formation  of 
neurofibrillary tangles, senile plaques and synapse and selective neuronal 
loss that progress slowly and leaves end stage patient’s bed ridden. 
Deposition of βA has been presented as major culprit of AD pathogenesis. 
The ultimate goal is to block the formation of βA oligomers and fibrils to 
inhibit the fibrilization and fibrilization-dependent neurotoxicity. Using this 
kind of approach, however need detailed study of molecular nature of 
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secretases and also mechanism as to how do it interact with presenilin. 
Does it stop the cognitive decline in AD patients and what toxicity will β-
and γ-secretases inhibitor have, present a major academic challenge and 
thus central to the future developments of a rational molecular therapy for 
AD. To date, it remains unknown in which percentage of patients 
hereditary factors are the cause of the disease. However, it is widely 
accepted that, apart from the above-mentioned mechanism of AD 
pathology, a substantial part of the disease is of multifactorial origin, with 
oxidative stress, mitochondrial dysfunction, inflammation and 
environmental factors. For this reason, the treatment will also be complex 
and might require different interventions for treatment. Being multifactorial 
pathogenicity of the disease, it is our opinion that a combined molecular, 
genetic and biochemical approaches should be employed for the 
development of drugs that can delay the onset of AD. The knowledge 
derived from these approaches could be extended from animal models to 
therapy of symptomatic AD patients. 
 
1.4 PURINES IN THE CENTRAL AND THE PERIPHERAL 
NERVOUS SYSTEM 
 
1.4.1 HISTORICAL OVERVIEW 
Purine bases and their pyrimidine counterparts are the building blocks of 
the nucleic acids that form deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA). ATP is considered the universal cellular energy currency; as 
well as other purine nucleotides and nucleosides, it is involved in 
biochemical pathways and energy transfer within the cell. Cyclic 
nucleotides such as adenosine 3':5'-cylic monophosphate (cAMP) and 
guanosine 3':5'-cylic monophosphate (cGMP) act as important intracellular 
second messenger molecules during signal transduction. Although purines 
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have been traditionally viewed as having only intracellular roles, about 80 
years ago Drury and Szent-Gyorgyi (1929) discovered that extracellular 
adenosine is a hormone released by the heart during ischemia. Over the last 
30 years, however, the roles of adenosine and ATP as neurotransmitters 
and neuromodulators in the central, peripheral and enteric nervous systems 
have been elucidated (Burnstock, 1991). Specific receptors for ATP 
(Abbracchio, 1994) and adenosine (Fredholm, 1988) have now been 
identified. Outside the nervous system, adenosine and ATP were found to 
act not only as neurotransmitters, but also as hormones with “trophic” 
roles. Trophic substances affect the development, structure (or) and 
maintenance of a target cell or tissue over a characteristically longer time 
course than the milliseconds to seconds involved in neurotransmission. 
Trophic effects include the plastic changes involved in memory and 
learning, collateral sprouting of nerve processes, neuroprotection against 
noxious stimuli and even regulation of cells number through induction of 
apoptosis. In addition to their well-documented functions as 
neurotransmitters and modulators in the central, peripheral and enteric 
nervous systems (Burnstock, 1991), work from several laboratories has 
indicated a direct trophic role for extracellular purines in the development 
and maintenance of the nervous system and its response to disease or injury 
(Neary, 1996). For example, purine nucleotides may regulate neurite 
outgrowth (Gysbers, 1992; 1996), the proliferation of glial cells 
(Abbracchio, 1994; Pettifer, 1994; Kim, 1991; Neary, 1996) and of brain 
capillary endothelial cells (Rathbone, 1999). Purines have also been shown 
to regulate neurotrophin and pleiotrophin synthesis and release 
(Middlemiss, 1995; Ciccarelli, 1997), and to play a role in the activation of 
microglia and in glial scarring (Neary, 1996). Potentially, purine 
nucleotides and nucleosides may act as trophic agents on the cells of the 
nervous system in several ways. They may target glial cells directly, 
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inducing functional changes which modulate neuronal differentiation and 
they may stimulate the synthesis and the release of trophic factors from 
neuronal and non neuronal cells. Purines may enhance the effects of growth 
factors on their target cells and they may interact directly with neurons or 
neuronal precursors, eliciting neuritogenesis, biochemical differentiation, 
or the maintenance of existing neuritis or enhancing neuronal survival. 
Also purine nucleotides and nucleosides may act as trophic agents through 
a combination of these actions. 
 
1.4.2 SOURCE OF PURINES IN THE CENTRAL AND 
PERIPHERAL NERVOUS SYSTEMS 
 
If extracellular purines play physiological and pathological roles, they must 
be present at effective extracellular concentrations. The extracellular 
concentrations of purines depend on several factors which include the 
amount of purines released, the local extracellular volume, uptake 
mechanisms which internalize extracellular purines and the presence of 
extracellular enzymes which metabolize purines. Potential sources of 
extracellular purines in the nervous system include: cellular sources, from 
damaged, necrotic or lysed cells and release from neurons, glia, endothelial 
cells and platelets. Neurones and glia release purine nucleotides and 
nucleosides at rest and upon stimulation even if the molecular mechanisms 
of their release is greatly different from each others. ATP and GTP co-
localize in synaptic vesicles of adrenergic, cholinergic and purinergic 
neurons and are released following depolarization by exocytosis. In 
astrocytes, ATP are probably released through some P-glycoprotein 
channels. Both glia and neurons have nucleoside transport systems which 
play an important role in regulating the extracellular concentrations of 
purine nucleosides. Once released extracellularly, purine nucleotides and 
nucleosides undergo a complex extracellular metabolism by many cell 
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surface located enzymes which have the same function of the 
corresponding intracellular enzymes. In fact, intracellularly, enzymatic 
mechanisms provide for the salvage of purine nucleosides and bases, thus 
assuring the continuous synthesis of ribo- and deoxyribo-nucleotidases and 
cholesterol precursors. But, extracellular nucleosides may undergo further 
metabolism. Adenosine deaminase (Ada), which converts adenosine (Ado) 
to inosine (Ino), is predominantly a cytosolic enzyme, which helps to 
maintain a strict control of Ado levels, thus avoiding the cytotoxic actions 
of Ado and especially deoxyadenosine in peripheral tissues as well as in 
brain. Intracellular Ino, or hypoxanthine (Hypo) derived from Ino by the 
activity of purine nucleoside phosphorylase (PNP), may be reutilized for 
salvage of inosine 5’monophosphate synthesis. This is a crucial point for 
metabolic recycling of both adenine- and guanine-based intracellular purine 
nucleotides (Harkness, 1988). Ada is also associated with the external 
surface of the cells in the CNS (Ciruela, 1996). Ada activity is most 
prominent in glia, where its activity is at least five times that in peripheral 
ciliary ganglion neurons and nine-fold that in central neurons (Ceballos, 
1994). Ada has also been found on synaptosomes and synaptic vesicles, 
which also contain other ectoenzymes such as 5' nucleotidase and ecto-
adenosine triphosphatase. The combined effect of ecto-5'-nucleotidase, 
nucleoside transport and Ada may serve to regulate the effective local 
concentration of Ado and therefore the extent of adenosine receptor 
activation. Indeed, binding of Ada to the A1 receptor enhances the affinity 
of the A1 adenosine receptor for its ligands, suggesting Ada enhances 
coupling between the A1 receptor and heterotrimeric G-proteins, thus 
increasing the ligand-induced second messenger production (Ciruela, 
1996). Thus Ada, in addition to metabolizing Ado, may also facilitate 
signal transduction via the A1 receptor. Specific mention must be made of 
the metabolic fate of guanine (Gua) (Fig 6). Guanosine (Guo) and Gua are 
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readily interconvertible by PNP while Gua is deaminated by guanine 
deaminase (guanase), in an essentially irreversible reaction. The activity of 
guanase shows marked regional variations, up to 50 - fold, in various parts 
of the CNS. Guanase activity is high in the olfactory bulb and in the 
hippocampus but very low in the pons, medulla and cerebellum. Large 
regional variations in the activity of a brain enzyme often implies that it is 
associated with neurotransmitter metabolism. This has led several 
investigators to suggest that Guo may be a neurotransmitter in the CNS 
(McGeer, 1987). 
 
 
 
 
Figure 6: Intracellular metabolism of guanine-based purines. 
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1.4.3 GUANOSINE 
Guo participates in structural and regulatory components of cells, but also 
exists extracellularly (Ciccarelli, 1999). In brain, extracellular guanine-
based purines are primarily released from glial cells, likely mostly as 
nucleotides that are metabolized by ectonucleotidases to extracellular Guo 
(eGuo) (Ciccarelli, 2001). Stimulation of astrocyte cultures by, for 
example, combined oxygen-glucose deprivation or field electrical 
stimulation markedly increases eGuo (Ciccarelli, 1999), and in vivo focal 
brain injury elevates eGuo for up to 1 week. eGuo exerts numerous 
neurotrophic effects including: proliferation of glial cells, neurite 
outgrowth (Gysbers, 1996) synthesis and release of purines and trophic 
factors, such as nerve growth factor (NGF), from several cell types 
(Middlemiss, 1995; Di Iorio, 2001; Ciccarelli, 2000; Gysbers, 1992); and 
anti-apoptotic effects (Di Iorio, 2002; Di Iorio, 2004). It is suggested that 
the effects of Guo are mediated through putative G-protein linked cell-
surface receptors (Traversa, 2002; Caciagli, 2000). Although the 
localization of guanine deaminase described above raises the possibility 
that eGuo and eGua may also play a role in synaptic transmission, most 
effects of eGuo thus far delineated in the CNS appear to be ‘trophic’, 
regulating cell growth, differentiation and survival. eGuo stimulates the 
proliferation of astrocytes in vitro (Kim, 1991), apparently due at least in 
part to the presence of very small quantities of contaminating microglia in 
the cultures, since the effects of Guo were increased in proportion to the 
number of microglia present (Ciccarelli, 2000). Guo apparently stimulated 
the release of interleukin-1 (Il-1) by microglia, which stimulates astrocyte 
proliferation. However, eGuo also stimulates proliferation of other cell 
lines that do not contain microglia, so it likely also directly affects 
proliferation of some cell types. In addition to its effects on microglia, 
eGuo also enhances the synthesis of NGF and basic fibroblast growth 
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factor (bFGF) mRNA in cultured mouse astrocytes (Middlemiss, 1995; 
Gysbers, 1992), and NGF and transforming growth factor β1 (TGFβ1) from 
rat astrocytes (Di Iorio, 2001). Not only does eGuo promote synthesis and 
release of peptide trophic factors but also eGuo stimulates release of 
adenine-based purines including adenosine. Exposure of astrocytes to 300 
µM eGuo for 1 hour increased extracellular levels of endogenous adenosine 
in culture medium by 1,5 fold (Ciccarelli, 2000). This may contribute to the 
trophic effects of eGuo. A further biological effect of Guo that has been 
studied extensively is its ability to stimulate outgrowth of nerve processes 
(neurites). eGuo promotes neurite outgrowth in PC12 cells and also 
synergistically enhances NGF-dependent neurite outgrowth (Gysbers, 
1996; 1992). PC12 cells treated with 300 µM Guo for 48 hours 
demonstrated neurite extensions in 6% of PC12 cells, significantly more 
than control conditions (Gysbers, 1996). The presence of 40 ng/ml of 2,5S 
NGF resulted in 20-35% of PC12 cells with neurite extensions, and the co-
presence of 300 µM Guo with 40 ng/ml of 2,5S NGF resulted in 40-65% of 
PC12 cells with neurite extensions following 48 h (Paletzki, 2002). 
Moreover, primary cultures of fetal mouse neurons responded with neurite 
outgrowth to much lower concentrations of eGuo - 1 to 100 µM (Rathbone, 
1998). Finally, eGuo has been shown to have neuroprotective effects in 
vitro and in vivo. Anti-apoptotic effects of eGuo have also been observed in 
astrocytes; cultures exposed to eGUO 1 hour before staurosporine had 
significantly fewer apoptotic cells than those exposed to staurosporine 
alone - 23% and 54% respectively (Di Iorio, 2004). Apoptosis induced by 
βA in SH-SY5Y human neuroblastoma cells was also reduced by eGuo 
(Pettifer, 2004). 
 
Although these trophic effects of eGuo are well established, the way in 
which eGuo produces its effects is only now being elucidated. Initially, the 
-   32 -
Introduction 
mitogenic effects of eGuo on astrocytes appeared be mediated in part 
through adenosine receptors, since the effects were at least partly inhibited 
by theophylline, an adenosine receptor antagonist (Kim, 1991). In a variety 
of primary and tumor cell lines from chicks, mice and humans the effects 
of eGuo were inhibited by 1,3-dipropyl-7-methylxanthine (DMPX), an 
adenosine A2 receptor antagonist, but not by 1,3,-dipropyl-8-(2-amino-4-
chorophenyl)xanthine (PACPX), an A1 antagonist. And the ability of eGuo 
to stimulate [3H]thymidine incorporation into cultures of rat fetal astrocytes 
was also partially inhibited by A1 and A2B receptor antagonists (Ciccarelli, 
2000). Although the effects of eGuo on neurite outgrowth were also found 
to have a component that could be explained by eGuo-induced increases in 
extracellular adenosine in the medium (Gysbers, 1996), eGuo had a distinct 
extracellular effect unrelated to adenosine. Indeed, the neuritogenic effects 
of Guo were not inhibited by nitrobenzylthioinosine (NBTI) or 
dipyridamole, nucleoside transport inhibitors, suggesting Guo exerts its 
effects at the cell-surface (Gysbers, 1996; 1992). It has been found that 
Guo-induced effects on astrocytes are partially inhibited by purinergic 
receptor antagonists; however, Guo does not bind adenine purinoceptors 
with high affinity (Muller, 1993) and Guo did not act through an A1/A2 
receptor, suggesting it may exert neuritogenic effects through its own cell-
surface receptor (Gysbers, 1996; 1992). These considerations prompted a 
successful search for distinct Guo binding sites on cultured astrocytes and 
in whole rat brains (Di Iorio, 2001; Traversa, 2002). These have 
characteristics of G-protein coupled receptors. Subsequently it is apparent 
that eGuo activates intracellular signalling pathways that are apparently 
related to presumptive Guo receptors. Thus, for example, the anti-apoptotic 
effects of eGuo on βA-induced apoptosis in SH-SY5Y cells were inhibited 
by pretreatment with LY294002, a PI3K inhibitor, and PD98059, an MEK 
inhibitor. Guo further increased phosphorylation of Akt/PKB, which was 
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also abolished by LY294002 and PD98059 treatment (Pettifer, 2004). 
Similarly, in astrocytes exposed to the apoptosis-inducing agent 
staurosporine, eGuo reduces apoptosis and this effect is antagonised by pre-
treatment with pertussis toxin (PTX). Differently, in this case, the eGuo 
effect was antagonized by SB202190 (an inhibitor of p38 MAPK pathway). 
eGuo also inhibited effects of glycogen synthase kinase-3β (GSK-3β), a 
pro-apoptotic enzyme a downstream target of the PI3K/Akt/PKB pathway 
(Di Iorio, 2004). Furthermore, Guo promoted upregulation of mRNA and 
protein expression of Bcl-2, an antiapoptotic protein and another 
downstream target of the PI3K/Akt/PKB pathway (Di Iorio, 2004). Thus 
eGuo appears to exert effects through both the p38 MAPK and the 
PI3K/Akt/PKB pathways. Signalling pathways involved in promotion of 
neurite outgrowth by eGuo are similar to those implicated in its anti-
apoptotic effects. Guo treatment has been shown to promote increases in 
intracellular cAMP in astrocytes (Rathbone, 1991) and PC12 cells 
(Gysbers, 1996). Increases in cAMP were inhibited by SQ22536, an 
inhibitor of adenylate cyclase; however, neurotrophic effects of Guo were 
only partly inhibited (Gysbers, 1996). These findings suggest that Guo-
induced effects are mediated by both cAMP-dependent and -independent 
mechanisms (Rathbone, 1991). Guo activated cAMP-dependent 
mechanisms are suggested to activate the MAPK cascade and potentially 
other protein kinases (Rathbone, 1991). Guo-induced effects are abolished 
by PTX, wortmannin and PD98059, MAPK inhibitors, suggesting Guo acts 
on a Gi-protein coupled cell-surface receptor to activate the MAPK 
pathway. Within the MAPK pathway, Guo has been found to activate and 
stimulate phosphorylation of MAP kinases ERK-1 and -2 in cultured 
astrocytes that may act to promote NGF synthesis and release (Di Iorio, 
2001; Gysbers, 1992; Rathbone, 1998). The MAPK cascade has been 
identified as the major pathway by which NGF induces growth and 
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differentiation in PC12 cells (Rathbone, 1999) and may therefore represent 
a convergent mechanism for NGF and Guo. The biological significance of 
eGuo in vivo is only just beginning to be understood and the field is fertile 
for further exploration. Increases in eGuo are likely a natural response to 
injury, since eGuo is elevated for prolonged periods after experimental 
brain injury. But the new data indicating that it may also affect quiescent 
progenitor cells in the nervous system raise the possibility that the effects 
of eGuo potentially extend to more chronic situations as well as to acute 
injury. Moreover, manipulation of eGuo concentration may be of potential 
therapeutic value in certain pathological conditions. Studies of the 
metabolism of eGuo will of great importance. For example, it may 
elucidate the functional interrelationship of the extracellular guanine-based 
purine nucleotides, Guo and Gua. Extracellular guanine nucleotides also 
have trophic effects on cell proliferation (Rathbone, 1992; Kim, 1991), as 
well as differentiation of neurons (Gysbers, 1996; Rathbone, 1998) and 
myoblasts (Pietrangelo, 2002). Therefore their extracellular conversion to 
Guo may be one level at which their biological effects can be regulated. 
Moreover, the presence of high concentrations of guanine deaminase in 
certain discrete populations of neurons (Paletzki, 2002) imply that Guo and 
Gua have important extracellular roles in brain that extend beyond the 
trophic effects that have been elucidated to date. It is attempting to unravel 
the roles of these intriguing non-adenine-based purines. Better 
comprehension of their biological effects, their metabolism and the 
mechanisms through which their effects are mediated may prove useful not 
only in understanding physiological and pathological processes in the CNS, 
but also in targeting interventions for several pathological conditions. 
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2. AIM OF THE STUDY 
 
AD is the most common age-related neurodegenerative disorder, and 
one of the most devastating diagnosis that patients and their families can 
receive. The clinical symptoms result from the deterioration of selective 
cognitive domains, particularly those related to memory (Oddo, 2008). AD 
is characterized by progressive memory loss and deficit of cognitive skills. 
The pathological hallmarks of AD include selective damage to synapses 
and neurons, neurofibrillary tangles, activated glia and presence of senile 
plaques (Selkoe 2001). βA is the major constituent of senile or amyloid 
plaques found in the brains of AD patients. βA is derived from the 
processing of the amyloid precursor protein, and it is thought to play a 
critical role in the onset or progression of AD (Ramalho, 2004). 
Pathological, biochemical and genetic evidences favour the ‘amyloid 
hypothesis’ of AD, although understanding this evidence requires an 
appreciation of how the βA peptide is produced (Wolfe, 2002). Different 
studies suggest that βA plays a central role in the pathogenesis of neuronal 
dysfunction in AD. In fact, amyloid oligomers, which represent 
intermediates in the fibril formation process, could be primarily responsible 
for amyloid pathogenesis, rather than the mature fibrils that accumulate as 
large aggregates (Hardy, 2002; Kayed, 2003). Growing evidences suggest 
that alterations in the UPS function may be involved in AD pathogenesis. 
For instance, amyloid oligomers can disrupt ion homeostasis inside and 
outside the cell and can interfere with the UPS. The soluble oligomers 
might serve as “all-purpose” β strands that can interact with transiently 
unfolded or nascent proteins, where interior β sheet edges are exposed. The 
proteins, trapped in misfolded states through this interaction, become 
substrates for ubiquitination, targeting them for proteasomal degradation. 
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This “misfolding trap” mechanism could potentially act in concert with 
other deleterious amyloid interactions, with proteasomes and chaperone 
proteins for example, ultimately overloading the UPS (Gruschus, 2008). 
This view is supported by evidence showing that in AD brains ubiquitin 
accumulates in both plaques and tangles. The accumulation of βA and tau 
makes AD a proteins-misfolding disease, or proteopathy, and suggests that 
alterations in protein quality control mechanisms may be directly or 
indirectly involved in the disease pathogenesis (Oddo, 2008). 
Understanding the molecular pathways by which the various 
pathological alterations compromise neuronal function and integrity and 
lead to clinical symptoms has been a long-standing goal of AD research. 
Purines and purine nucleotides are essential constituents of all living 
cells. ATP is used as an energy source for nearly all cellular activity, 
whereas adenine is a component of nucleic acids. Perhaps as a result of 
their ubiquitous nature, purines have also evolved as important molecules 
for both intracellular and extracellular signaling, roles that are distinct from 
their activity related to energy metabolism and the genetic transmission of 
information. Extracellular brain concentrations of purines - such as 
adenosine, Guo and inosine - are markedly elevated by a diverse array of 
pathological stimuli. Many of the effects of purines that are observed to a 
minor extent under normal conditions are greatly augmented during 
pathological events and are neuroprotective in that context (Ciccarelli, 
1999; Hasko, 2004; Dunwiddie, 2001). 
The aim of the study was to investigate the protective role afforded 
by the guanine-based purine nucleoside, Guo, in cellular cultures exposed 
to βA25-35 and βA1-42, specific neurotoxins able to reproduce Alzheimer’s 
disease in SHSY5Y cells, a human neuroblastoma cell line. Different 
aspects involved in βA-induced toxicity were studied. Firstly, 
mitochondrial dysfunction and translocation of phosphatidylserine (PS), a 
-   37 -
Aim of the study 
marker of apoptosis, were evaluated using MTT and Annexin-V assay, 
respectively. As a following step, we investigated the basic mechanism of 
neuroprotective effects of Guo against βA peptide-induced toxicity and we 
supposed that neuroprotection of Guo can be ascribed to its ability to 
modulate proteasome activity levels, using lactacystin, a specific inhibitor 
of proteasome. To rule out the possibility that Guo increases proteasome 
activity, the chymotrypsin-like activity was assessed employing the 
fluorogenic substrate Z-LLL-AMC. In parallel, we evaluated the 
modulation of ubiquitinated protein levels at similar experimental 
conditions adopted. We then estimated an involvement of anti and pro-
apoptotic proteins, such as Bcl-2, Bad and Bax by western blot analysis. 
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3. EXPERIMENTAL PROCEDURES 
 
3.1 MATERIALS 
 
3.1.1 TREATMENTS 
The Guo (Fig. 7) was purchased from Sigma-Chemical Co. (St Louis, 
Missouri-USA). All other reagents were of the highest grade of purity 
commercially available. The stock solution (40 mM) was prepared 
according to the followings proportions: 1/10 of Guo stock (0,4 M in 
NaOH 1 N); 6/10 distilled water; 3/10 HCl 0,1 N. Then, the working 
solutions were prepared after dilution of the stock solution. 
 
Figure 7: Chemical structure of Guo. 
 
βA1-42-peptide was purchased from Sigma-Chemical Co., while βA25-35-
peptide from Bachem (Bubendorf-Switzerland). 
Figure 8 
 
 
H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-
Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-
Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH 
 
 
 
: SequenH-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH ces of βA1-42 and βA25-35. 
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βA-peptide preparation 
βA1–42 peptides were first dissolved in hexafluoroisopropanol to 1 mg/ml, 
sonicated, incubated at room temperature for 24 h and lyophilized. The 
resulting unaggregated βA1–42 film was dissolved with dimethylsulfoxide 
and stored at -20 °C until use. The βA1–42 aggregation to oligomeric and 
fibrillar forms were prepared as described previously by Maezawa et al. 
(2006) and Dahlgren et al. (2002), respectively. The morphology of 
oligomeric and fibrillar βA1–42 forms obtained was checked by transmission 
electron microscopy (TEM). 
 
3.1.2 CELL CULTURE 
Human neuronal-like SH-SY5Y cells were purchased from Interlab Cell 
Line Collection (ICLC Genova-Italy) and were routinely grown at 37°C in 
a humidified incubator with 5% CO2 in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 50 
U/ml penicillin and 50 µg/ml streptomycin (Lonza Group Ltd.-
Switzerland). To determine the neuroprotective effects of Guo, SH-SY5Y 
cells were seeded in 96-well plates at 3x104 cells/well, whereas to evaluate 
apoptosis and necrosis, the cells were seeded in 60-mm cultures dishes at 
1,5x106 cells/dish. To evaluate proteasome activity and protein levels by 
western blot analysis after treatment with Guo, cells were seeded in 100-
mm cultures dishes at 4x106 cells/dish. All experiments were performed 
after 24 hours of incubation at 37°C in 5% CO2 
 
 
 
 
 
 
Figure 9: SH-SY5Y neuroblastoma cells observed at optic microscope (10x). 
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3.2 METHODS 
 
 
3.2.1 TRANSMISSION ELECTRON MICROSCOPY (TEM)  
To analyze the morphology of aggregated βA1-42 forms, the TEM was used 
as previously reported by Gupta et al. (2007). Briefly, aggregated βA1–42 
solution (40 µM) was absorbed onto formvar-carbon coated grids (200 
mesh size) for 40 minutes and stained with 2% aqueous phosphotungstic 
acid solution before viewing with a Philips CM10 transmission electron 
microscope at 80 kV.  
 
 
3.2.2 CELL VIABILITY ASSAY 
The neuronal viability in terms of mitochondrial metabolic function was 
evaluated by the reduction of MTT to formazan. The assay is based on the 
cleavage of the yellow tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (Sigma-
Chemical Co.) to blue formazan crystals by metabolically active cells. 
Cultured cells were treated with βA25-35 and Guo at different concentrations 
and for different exposure times. Briefly, after removal of the treatment, 
SH-SY5Y cells were washed with phosphate buffered saline (PBS) and 
incubated with MTT (5 mg/ml) in PBS for 2 hours at 37°C in 5% CO2. 
After further washing, the formazan crystals were dissolved with 
isopropanol and measured (570 nm, ref. 690 nm) with a spectrophotometer. 
The neuronal viability was expressed as a percentage of control cells.  
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3.2.3 INTRACELLULAR REACTIVE OXYGEN SPECIES 
FORMATION (ROS) 
Cultured cells were treated with Guo at different concentrations and for 
different exposure times. Formation of intracellular ROS was determined 
using the non-fluorescent cell permeant compound 2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA), as previously reported 
(Rosenkranz, 1992). Following de-esterification by endogenous esterases 
its polar metabolite, which diffuses out of the cell far more slowly than its 
parent compound, can be oxidized by peroxides producing the fluorescent 
compound 2’,7’-dichlorofluorescein (DCF). The fluorescence of the cells 
from each well was measured using 485 nm excitation and 535 nm 
emission with a microplate spectrofluorometer (VICTOR3 VTM Multilabel 
Counter, Perkin Elmer, Wellesley, MA, USA). The values were expressed 
as the percentage increase of intracellular oxidative species evoked by 
exposure to Guo and calculated by the formula [100 x (Ft – Fnt)/Fnt], where 
Ft = fluorescence of treated cells and Fnt = fluorescence of non treated cells. 
 
 
3.2.4 APOPTOSIS AND NECROSIS ASSAY 
To determine the neuronal apoptosis and necrosis, the Annexin-V-FLUOS 
Staining Kit (Roche Diagnostics, Mannheim, Germany) was used 
according to the manufacturer's instructions. Cells were treated with Guo in 
presence of βA-peptide and Lactacystin (Sigma-Chemical Co.). The 
annexin-V binds phosphatidylserine exposed on the outside of the intact 
membrane of apoptotic cells whereas propidium iodide (PI) penetrates the 
broken membrane of necrotic cells and binds to DNA (Fig 10). The number 
of stained cells was counted by fluorescence microscopy and the values are 
expressed as percentages of annexin-V or PI-positive cells.  
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Figure 10: Schematic representation of the Annexin-V assay. 
 
3.2.5 PROTEASOME ACTIVITY 
After treatment of SH-SY5Y with Guo (25-75 µM) for 0-6 hours and/or 
inhibitors such as Lactacystin, LY294002 and PD98059 (Sigma-Chemical 
Co.), cells were washed with PBS, harvested, suspended in 50 mM 
Tris/HCl, and sonicated for 5 sec to lyse the cells. Protein concentrations 
were determined using the Bradford method (Bio-Rad, Milano-Italy). 
Proteasome activity was assayed by incubating 30 µg of protein with the 
proteasome substrate Z-LLL-AMC (carbobenzoxy-Leu-Leu-Leu-4-
methylcoumarinyl-7-amide) (Merck Chemicals Ltd-UK) (20 µM) in a total 
volume of 100 µl of assay buffer (0.38 mM EDTA and 50 mM Tris/HCl, 
pH 7.5) at 37 °C for 4 hours. As a negative control, 30 µg of a cell lysate 
protein sample was emploied. AMC (4-methylcoumarinyl-7-amide) 
liberated from the substrate by proteasome activity was determined by 
measuring fluorescence (excitation, 380 nm; emission, 450 nm; Wallac-
Victor2), and reading from an AMC standard curve. 
 
3.2.6 WESTERN BLOTTING 
Western blot analysis was used to detect Ubiquitin, Bad, Bax and Bcl-2 
protein levels (SantaCruz Biotechnology Inc-USA). Cultured cells were 
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treated with 75 µM of Guo at different exposure times. At the end of the 
drug treatment times, cells were washed twice with ice-cold PBS and then 
harvested at 4°C in a lysis buffer (25 mM Tris buffer, pH 7.4, containing 
150 mM NaCl, 100 µM sodium orthovanadate, 1.5 mM MgCl2, 1.0 mM 
EDTA, 1.0 mM EGTA, 1% NP40, 10% glycerol, 1 mM PMSF, 5 µg/ml 
leupeptin, 5 µg/ml aprotinin). After 20 min on ice cells were centrifuges at 
14,000 rpm for 10 min at 4°C. Supernatant aliquots were used for 
determination of protein concentrations by Bradford method. Protein were 
diluted in Laemmli-SDS sample buffer and boiled for 5 minutes. Equal 
amounts of protein were loaded into each lane of 12% SDS-PAGE gel and 
resolved at 80 V constant. Gels were transferred onto nitrocellulose 
membrane (Sigma-Chemical Co.) at 100 V constant for 60 minutes at room 
temperature, and membranes were blocked in blocking buffer (PBS, 0.1% 
Tween-20 with 5% w/v non fat dry milk) for 2 h. Blots were incubated 
overnight at 4°C with specific primary antibodies. All primary antibodies 
were diluted 1:1000 in primary antibody dilution buffer (PBS, 0.1% 
Tween-20 with 2,5% w/v non fat dry milk). After washing three times for 
15 min each with wash buffer (PBS, 0.1% Tween-20) membranes were 
exposed to a secondary antibody diluted 1:2,500 for 1 h at room 
temperature. Immunocomplexes were visualized using the enhancing 
chemiluminescence ECL kit, (GE-Healthcare, Milano-Italy) detection 
system. Densitometric analysis were performed for the quantification of the 
immunoblots using the Quantity One 1-D Analysis Software (Bio-Rad). 
 
3.2.7 STATISTICAL ANALYSIS  
Data are reported as mean ± SD of at least 3 independent experiments. 
Statistical analysis was performed using one-way ANOVA and the Dunnett 
post hoc test was used. Differences were considered significant at p<0.05. 
Analyses were performed using PRISM 3 software on a Windows platform.
-   44 -
Results 
4. RESULTS 
 
4.1 GUANOSINE CITOTOXICITY 
 
In order to study Guo citotoxicity in SH-SY5Y cells, mitochondrial 
activity loss was evaluated by MTT assay, ROS formation by a fluorimetric 
detection with DCF-DA and the translocation of phosphatidylserine (PS), a 
marker of apoptosis, using Annexin-V assay. 
SH-SY5Y cells were treated with Guo at a concentration range of 12,5-400 
µM for 24 hours. Treatment of SH-SY5Y cells with Guo for 24 hours 
caused loss of mitochondrial activity only at concentrations higher than 100 
µM. Starting from 200 µM, we found a 20% loss of mitochondrial activity. 
Concentrations lower than 100 µM did not compromise cell viability after 
24 hours of exposure (Fig.11a).  
In the same experimental conditions, we evaluated free radical formation 
induced by 45 mins exposure of SH-SY5Y cells to Guo. Results 
demonstrated that similar concentrations of Guo induced free radical 
formation in a dose-dependent manner. In particular, neurons showed a 
significantly increase in ROS production at a concentration of 100 µM, 
with a maximum effect observed at 400 µM (40%) (Fig. 11b). Cell death 
was evaluated by Annexin/Propidium Iodide staining kit. Treatment of SH-
SY5Y cells with Guo for 24 hours induced a strong and a dose-dependent 
increase of necrotic cells, whereas no increases of apoptotic cell percentage 
were seen (Fig. 11c). 
The concentration of 75 µM has been chosen to study the neuroprotective 
activity of Guo against βA peptide-induced toxicity in SH-SY5Y cells. 
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Figure 11: Effects of Guo in SH-SY5Y cells on (a) mitochondrial activity; (b) ROS 
formation; (c) apoptotic and necrotic cells formation. (*p<0.05; ***p<0.001 vs 
untreated samples; ANOVA with Dunnett post hoc test). 
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4.2 β-AMYLOID TOXICITY 
 
In order to study βA-induced toxicity in neurons, cell viability 
reduction was evaluated by MTT assay. We first evaluated the neuronal 
damage induced by treatment with βA25-35 fragment. βA25-35 peptide is often 
used for modeling different aspects of AD. The 11-amino acid fragment is 
a C-terminal peptide of βA1-42 located in its hydrophobic functional 
domain. MTT reduction method was used to determine cell viability and to 
provide information on mitochondrial function. 
The dose-dependent effect of βA25-35 on cell viability was assessed after 24 
hours of exposure. SH-SY5Y cells were treated with βA25-35 at a 
concentration range of 0,01-100 µM. Treatment of neuronal cells induced a 
similar decrease of mitochondrial activity starting at 1 µM. Concentrations 
lower than 1 µM did not compromise cell viability (Fig 12a). According to 
the cell viability results, the EC50 value was approximately 1 µM; so this 
concentration was used for the following experiments. 
We also evaluated the time-dependent cell viability reduction after 
treatment for 1-24 hours. βA25-35 treatment reduced cell viability at all the 
exposure times explored, starting from 1 hour (Fig. 12b). 
To determine whether βA25-35-induced cell death was attributed to 
apoptosis, the cells were exposed to 1 µM of peptide for 1-24 hours. Figure 
12c showed the percentage of apoptotic and necrotic cells after treatment 
with βA25-35. According to Annexin/propidium iodide double-dying results, 
the apoptotic cell death increased after 3 hours of treatment and the effect 
was almost the same until 24 hours of treatment. Instead, necrotic cell 
death increased after only 1 hour of βA25-35 treatment.  
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Figure 12: Effects of βA25-35-toxicity in SH-SY5Y cells on (a) dose-dependent cell 
viability after 24 h; (b) time-dependent cell viability after treatment with 1 µM; (c) time-
dependent apoptotic and necrotic cells formation after treatment with 1 µM. 
(***p<0.001 vs untreated samples; ANOVA with Dunnett post hoc test). 
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βA can exist in multiple assembly states - monomers, oligomers, 
protofibrils and fibrils - and it is the ability of this peptide to form fibrils 
and other intermediate states that impart the unique pathophysiological 
characteristics that define AD. Oligomeric and protofibrillar species are 
considered potent blockers of long-term potentiation, a form of synaptic 
plasticity. Based on this evidence, we then evaluated the kinetics of βA1-42 
aggregation to oligomeric and fibrillar forms by transmission electron 
microscopy (TEM). As shown in Fig. 13a, the aggregation process started 
after 24 hours of incubation at 37°C (oligomers) and after 48 hours in the 
same conditions oligomers and protofibrils coexisted in the preparation 
(fig. 13b). The aggregation process was complete after 5 days when the 
presence of fibrils was evident (fig. 13c). 
 
a b
 
 
 
 
 
 
 
                            OLIGOMERS                                                 PROTOFIBRILS 
 
c 
 
 
 
 
 
 
                                                                     FIBRILS 
Figure 13: Aggregation kinetics of βA1-42 peptide [40 µM] in physiologic conditions. 
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We also estimated the effects of treatment with oligomeric and fibrillar 
forms of βA1-42 (1 µM). The apoptotic and necrotic cell death was induced 
by βA1-42 treatment for 1-24 hours. According to Annexin/propidium iodide 
double-dying results, the oligomeric form showed an increase of the 
apoptotic cell death after 3 hours of treatment, with a maximum peak 
observed at 15 hours. Necrotic cell death increased after 15 hours of 
oligomeric βA1-42-treatment (Fig. 14a). Instead, the fibrillar form showed 
an increase of the apoptotic cell death after only 1 hour of treatment and the 
necrotic cell death increased after 6 hours (Fig. 14b). 
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Figure 14: Apoptotic and necrotic cell death in SH-SY5Y cells after several times of 
exposure with (a) βA1-42 oligomeric form and (b) βA1-42 fibrillar form. 
 
 
4.3 PROTECTIVE EFFECTS OF GUANOSINE 
 
The protective effects of Guo against βA25-35-induced neurotoxicity, 
was investigated in terms of cell viability loss in SH-SY5Y cells by using 
MTT assay. In particular, SH-SY5Y cells were treated with Guo during the 
βA25-35 short-term exposure. SH-SY5Y cells treatment for 3 hours with 
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Guo prevented the decrease in neuronal viability induced by βA25-35 (1 
µM). The toxicity induced by βA25-35 was significantly reduced by 
cotreatment with 50 and 75 µM of Guo (Fig. 15a). To confirm these effects 
we also evaluated apoptosis and necrosis, at long term exposure, using 
Annexin-V Fluos Staining Kit. SH-SY5Y cell treatment for 24 hours with 
Guo (75 µM) after βA25-35 exposure showed an inhibitory effect on βA25-35-
induced apoptosis but not necrosis (Fig. 15b). 
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Figure 15: Protective effects of Guo on βA25-35-induced cell death in SH-SY5Y cells: 
(a) neuronal viability after cotreatment for 3h; (b) apoptosis and necrosis after 
cotreatment for 24h. (***p<0.001 vs untreated samples; §§§ p<0.001 vs treated with Aβ 
alone. ANOVA with Dunnett post hoc test). 
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Subsequently, we determined whether the anti-apoptotic effects of Guo 
were also observed with oligomeric and fibrillar form of βA1-42 (1 µM). As 
shown in Figure 16, SH-SY5Y cell treatment with Guo (75 µM) after both 
oligomeric and fibrillar βA1-42-exposure showed an inhibitory effect on 
βA1-42-induced apoptosis, but not on necrosis. 
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Figure 16: Cell death in SH-SY5Y cells treated with 1 µM of (a) oligomeric and (b) 
fibrillar form of βA1-42 in presence of Guo 75 µM for 24 h. (***p<0.001 vs untreated 
samples; §§§ p<0.001 vs treated with Aβ alone. ANOVA with Dunnett post hoc test). 
 
4.4 INVOLVEMENT OF PROTEASOME IN GUO 
NEUROPROTECTION 
 
To investigate whether neuroprotection of Guo can be ascribed to its 
ability to modulate proteasome activity levels, we used lactacystin, a 
specific and irreversible inhibitor of proteasome. We co-administered Guo 
(25-75 µM) and lactacystin (2,5 µM) with βA peptides (1 µM) (all the 
peptides in study), to SH-SY5Y. We used non apoptotic concentrations of 
the all compounds. As shown in fig. 17, the antiapoptotic effects observed 
with Guo were completely abolished by lactacystin. 
To rule out the possibility that this effects resulted from an increase in 
proteasome activity induced by Guo, the chymotrypsin-like activity was 
assessed employing the fluorogenic proteasome substrate Z-LLL-AMC. 
The treatment of SH-SY5Y with Guo (75 µM for 0-6 h) induced a strong 
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time and dose-dependent increase of proteasome activity, with a peak at 2 
hours treatment with 75 µM Guo. In similar experimental conditions, 
western blot analysis didn’t show any increase of ubiquitinated protein 
levels. 
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Figure 17: Apoptosis in SH-SY5Y cells treated with 1 µM of (a) monomeric βA25-35, (b) 
oligomeric and (c) fibrillar form of βA1-42 in presence of Guo 75 µM and Lactacystin 
2,5 µM for 24 h. (***p<0.001 vs untreated samples; §§§ p<0.001 vs treated with Aβ 
alone. ANOVA with Dunnett post hoc test). 
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Figure 19: Ubiquitinated protein levels after treatment with Guo (75 µM) in SH-SY5Y 
cells for several times. 
 
 
 
It is known that Guo is able to activate the PI3-Kinase pathway in rat 
cultured astrocytes as well as in mouse microglia (Di Iorio, 2004; 
D’Alimonte, 2007) and to determine a marked ERK1/2 and p38 
phosphorylation in mouse microglial cells (D’Alimonte, 2007). So, in order 
to evaluate signal transduction pathways involved in Guo-induced up-
regulation of proteasome activity, SH-SY5Y cells were treated with Guo 
(75 µM) in presence of specific inhibitors of the proteasome (Lactacystin), 
of PI3K/Akt/GSK3β (LY294002) and of ERK1/2/MAPK (PD98059) 
survival pathways. As shown in fig. 20, the co-treatment of neurons with 
Guo and the specific inhibitors did not increase the proteasome activity. 
According to our results, Guo neuroprotection was completely abolished by 
the specific inhibitor of proteasome. Guo-neuroprotection was also 
inhibited by LY294002 and PD98059, which could suggest that Guo acts 
on the proteasome through the activation of the survival pathways. 
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Figure 20: Proteolytic activities of proteasome in SH-SY5Y cells after treatment for 2 h 
with Guo (75 µM) and specific inhibitors: PD98059 (5µM); LY294002 (10 µM); 
Lactacystin (2,5 µM). 
 
 
 
 
4.5 GUANOSINE AND PROTEIN EXPRESSION LEVELS 
 
We then evaluated the capability of Guo to modulate anti- and pro-
apoptotic proteins such as Bcl-2, Bad and Bax by western blot analysis. 
The time course (0-6 hours) of the protein activation induced by Guo (75 
µM) was evaluated in SH-SY5Ycells. In particular, the analysis of anti-
apoptotic Bcl-2 and pro-apoptotic Bad showed a decrease after 30 mins and 
2 hours of treatment with Guo. Instead, Bax expression decreased after 30 
mins, with a minimum peak after 2 hours. With longer treatments values 
were not substantially modified (Fig. 21). 
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5. DISCUSSION 
 
In AD the progressive nature of neurodegeneration suggests an age-
dependent process that ultimately leads to degeneration of synaptic afferent 
systems, dendritic and neuronal damage, and the formation of abnormal 
protein aggregates throughout the brain. Diverse lines of evidence indicate 
that βA plays a central role in the pathogenesis of neuronal dysfunction in 
AD. Recent studies suggest that the relatively weak correlation between 
plaque burden and the severity of cognitive impairments might be 
explained by the activity of multiple different βA assembly forms and 
probably memory impairment could be mediated by soluble oligomers. In 
fact, amyloid oligomers, which represent intermediates in the fibril 
formation process could be primarily responsible for amyloid pathogenesis, 
rather than the mature fibrils that accumulate as large aggregates. The 
membrane integrity disruption by amyloid oligomers and the concomitant 
increase in intracellular calcium may be the proximate initiator of several 
pathogenic pathways, including reactive oxygen species (ROS) production, 
altered signaling pathways and mitochondrial dysfunction. Mitochondrial 
dysfunction may also feed back to upstream pathways that regulate the 
level of mis-folded proteins. The final step in AD is characterized by βA-
induced apoptosis, a mechanism of cellular death activated by 
mitochondrial pathway or by the interaction with specific neuronal cell-
surface receptors. The Bcl-2 family of proteins has a crucial role in 
intracellular apoptotic signal transduction. However, it is widely accepted 
that, apart from the above-mentioned mechanisms, AD is a complex 
multifactorial disorder. Guo exerts numerous neurotrophic effects 
including: proliferation of glial cells (Rathbone, 1992; Kim, 1991), neurite 
outgrowth (Gysbers, 1996), synthesis and release of purines and trophic 
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factors, such as nerve growth factor (NGF), from several cell types 
(Middlemiss, 1995; Rathbone, 1992; Di Iorio, 2001; Ciccarelli, 2000; 
Gysbers, 1994), and anti-apoptotic effects (Di Iorio, 2002; Di Iorio, 2004). 
It is suggested that the effects of GUO are mediated through putative G-
protein linked cell-surface receptors (Traversa, 2002; Caciagli, 2000). 
 
In the present study, it was interesting to evaluate the possible effect 
of Guo on toxicity induced by βA-peptide in human neuroblastoma cell 
line, SH-SY5Y cells. Guo has been reported to protect SH-SY5Y cells and 
rat primary astrocytes against apoptosis induced by βA-peptide and 
staurosporine, respectively (Pettifer, 2004; Di Iorio, 2004). The analisys of 
cell viability by MTT assay in presence of βA25-35, the neurotoxic core of 
βA-protein, was evaluated in a dose- and time-dependent manner. The 
dose-dependent treatment with βA25-35 for 24 hours induced a similar 
decrease of cell viability, starting at 1 µM. Whereas, the time-dependent 
treatment reduce cell viability at all the exposure times explored, starting 
from 1 hour. Besides, the annexin/propidium iodide results confirmed that 
apoptotic cell formation increased after 3 hours and necrotic cell formation 
after only 1 hour of βA25-35 treatment. We also evaluated the effects of 
treatment with oligomeric and fibrillar forms of βA1-42. According to 
Annexin/propidium iodide results, the oligomeric form showed an increase 
of the apoptotic cell death after 3 hours of treatment and the necrotic cell 
death increased after 15 hours of oligomeric βA1-42-treatment. Instead, the 
fibrillar form showed an increase of the apoptotic cell death after only 1 
hour of treatment and the necrotic cell death increased after 6 hours. We 
after employed the nucleoside Guo to evaluate the possible neuroprotection 
against toxicity induced by βA-protein. Exogenous Guo (75 µM), added to 
SH-SY5Y cells exposed to βA25-35 for 3 hours, showed a protective effect 
by significantly reducing cell death (about 60%). Also, this inhibitory 
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effects resulted to be evident after Annexin-V staining (about 64%). The 
anti-apoptotic effects of Guo were observed with oligomeric and fibrillar 
form of βA1-42. Growing evidence suggest that alterations in the UPS 
function may be involved in AD pathogenesis. The possibility that the 
protective effect of Guo was due to an involvement of the UPS has been 
demonstrated by using a specific inhibitors of proteasome, lactacystin. The 
co-treatment with lactacystin abolished completely the neuroprotective 
effects of Guo. To rule out the possibility that Guo-neuroprotection effects 
resulted from an increase in proteasome activity, the chymotrypsin-like 
activity of the proteasome has been valued in SH-SY5Y cell lysates, by 
assaying cleavage of Z-Leu-Leu-Leu-AMC. Results proved the increase in 
proteasome activity in a dose-dependent manner with a peak after 2 hours 
of treatment. Moreover, to exclude an alteration in the proteasome activity, 
we also demonstrated that no increase of ubiquitinated protein levels could 
be observed by western blot analysis. 
The MAP kinase/ERK1/2 signaling pathway is reported to play a critical 
role in the regulation of cell growth and differentiation (Crews, 1992; 
Alessi, 1994). In particular, it is known that it is essential for the normal 
development and functional plasticity of the CNS. It is also demonstrated 
that PI3K/Akt pathway plays an important role in a variety of biological 
processes including cell survival, proliferation, cell growth and glycogen 
metabolism (Franke, 1997; Vivanco, 2002; Hajduch, 2001). In recent 
studies it has been reported that Guo is able to activate the PI3-Kinase 
pathway in rat cultured astrocytes, as well as in mouse microglia (Di Iorio, 
2004; D’Alimonte, 2007); it also determines a marked ERK1/2 and p38 
phosphorylation in mouse microglial cells (D’Alimonte, 2007). Based on 
this evidence, we evaluated the effects of some inhibitors of the 
proteasome, PI3K/Akt/GSK3β and ERK1/2/MAPK on the Guo-induced 
up-regulation of proteasome activity. Lactacystin, LY294002 and PD98059 
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abolished the Guo-neuroprotection. This suggests that Guo might be able to 
act on the proteasome through the activation of the survival pathways. 
It is well known that another important downstream target of PI3K/Akt is 
the antiapoptotic protein Bcl-2. The Bcl-2 family consists of a number of 
evolutionarily conserved proteins that regulate apoptosis through the 
control of mitochondrial membrane permeability and release of cytochrome 
c. Released cytochrome c binds Apaf-1 (apoptotic protease activating 
factor 1) and forms an activation complex with caspase-9. In Bcl-2 family 
it is possible to distinguish two groups of proteins upon function and 
sequence homology: anti- and pro-apoptotic proteins. In the present 
research, we evaluated the intracellular levels of Bcl-2, Bad and Bax in SH-
SY5Y after Guo-exposure. Among these proteins, Bax expression resulted 
down-regulated (about 70%) after Guo-treatment, in according to Kalfon et 
al (2006). Thus, the mechanism of neuroprotection induced by Guo could 
involve a rapid degradation of pro-apoptotic proteins by the proteasome. 
 
It is attempting to unravel the roles of these intriguing non-adenine-
based purines. Better comprehension of their biological effects, their 
metabolism and the mechanisms through which their effects are mediated 
could be prove useful not only in understanding physiological and 
pathological processes in the CNS, but also in targeting interventions for 
several pathological conditions. Being multifactorial pathogenicity of the 
disease, it is our opinion that a combined molecular, genetic and 
biochemical approaches should be employed for the development of drugs 
that can delay the onset of AD. The knowledge derived from these 
approaches could be extended from animal models to therapy of AD 
patients.   
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8. APPENDIX 
 
The research object of the present thesis has been developed in compliance 
to the laws safety in environments of job (D.L.vo 626/94 and following). 
The experimental procedures are been performed in according to the 
Procedures Operational Standards (SOPs) of the laboratories of Genetic 
Toxicology of the Department of Pharmacology, University of Studies in 
Bologna as foreseen by the OECD-GLPs for the evaluation of the chemical 
mixtures. 
 
• OECD, 1982. Good Laboratory Practice in the Texting of Chemicals. 
• OECD, 1988. Final Report of the Working Group on Mutual 
Recognition of Compliance with Good Laboratory Practice. 
• CEE, 1986. Board directive of 18/12/86, concern the reapproaching 
of the legislative, regulation and administrative dispositions related 
to the application of the principles of good routines of laboratory and 
to the control of their application for the tests on the chemical 
substances (87/18/CEE). 
• Official gazette n. 198 of 27/8/86. DM 26/06/86: application of the 
principles of good practices of laboratory on the chemical substances 
and criterions for the release of the authorizations foreseen by the 
DPR n. 927/81, art. 6. 
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